Two medical therapies elevated to front line in 2021 update HF ECDP

Media formats available:

Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC.24
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
- James Januzzi, MD
Clinical implications of the evidence from IV iron trials in HF
Clinical implications of the evidence from IV iron trials in HF
Heart Failure
Clinical implications of the evidence from IV iron trials in HF
- Stefan D. Anker, MD, PhD
- Robert J. Mentz, MD, FHFSA, FACC, FAHA
- Piotr Ponikowski, MD, PhD, FESC, FHFA
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
Kidney Disease
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
- Antoni Bayés-Genís, MD, PhD
- Patrick Rossignol, MD, PhD
New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D
New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D
ESC Congress 2023
New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D
- Amy Groenewegen, MD

PACE-CME